Medical and procedural treatments for hair loss, including drug therapies, devices and regenerative approaches.
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Not applicable, Assiut University. Conditions: Androgenetic Alopecia; Cicatricial Alopecia. Interventions: Integrated Evidence-Based FUE Protocol; Standard FUE Practice. Investigational: trial-stage therapies are not approved for the use studied.
Phase 2, Pelage Pharmaceuticals, Inc.. Conditions: Androgenetic Alopecia. Interventions: PP405 0.05% Topical Gel; Topical Vehicle Gel. Investigational: trial-stage therapies are not approved for the use studied.
Phase 2/Phase 3, Pelage Pharmaceuticals, Inc.. Conditions: Androgenetic Alopecia. Interventions: PP405 0.05% Topical Gel; Vehicle Topical Gel. Investigational: trial-stage therapies are not approved for the use studied.
Al-Azhar University. Conditions: Diabete Mellitus; Female Androgenetic Alopecia; Dermoscopy. Interventions: . Investigational: trial-stage therapies are not approved for the use studied.
Reason: Labeling: Incorrect or missing lot and/or expiration date. Products were compounded using expired components.. Recalling firm: MPRX, Inc. dba Medical Park Pharmacy (TX). Status: Terminated.
Throne Biotechnologies Inc.. Conditions: Alopecia Areata; Alopecia Totalis; Alopecia Universalis. Investigational — not approved for the use studied.
Assiut University. Conditions: Androgenetic Alopecia; Cicatricial Alopecia. Investigational — not approved for the use studied.
Eurofarma Laboratorios S.A.. Conditions: Alopecia. Investigational — not approved for the use studied.
Pelage Pharmaceuticals, Inc.. Conditions: Androgenetic Alopecia. Results posted 2026-09-22. Investigational — not approved for the use studied.
University Hospital, Ghent. Conditions: Physical and Psychological Evaluation of Hormonal Therapy in Transsexual Persons. Investigational — not approved for the use studied.
Pelage Pharmaceuticals, Inc.. Conditions: Androgenetic Alopecia. Investigational — not approved for the use studied.
